Semaglutide vs. Tirzepatide: What the Latest Science Actually Shows

For the first time, researchers have put semaglutide and tirzepatide head-to-head in a rigorous clinical trial — and the results settled what had been a long-running debate in obesity medicine. The SURMOUNT-5 trial, published in 2025 in the New England Journal of Medicine, found that men and women with obesity who used tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% in those using semaglutide. That’s not a rounding error — it’s a clinically meaningful gap that has real implications for anyone evaluating these two medications.

Both drugs belong to the GLP-1 receptor agonist class, but they work through slightly different mechanisms. Semaglutide (sold as Wegovy for weight loss and Ozempic for diabetes) activates the glucagon-like peptide-1 receptor, which regulates appetite, insulin secretion, and gastric emptying. Tirzepatide (Zepbound for obesity, Mounjaro for diabetes) does all of that and adds activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor — making it a dual-agonist. That second pathway appears to meaningfully amplify outcomes, at least when it comes to fat loss.

How They Stack Up on Weight, Waist, and Blood Sugar

The SURMOUNT-5 data go beyond just total weight loss. Participants on tirzepatide also reduced their waist circumference by an average of 18.4 cm versus 13.0 cm for semaglutide — a difference that matters for metabolic health, since visceral fat around the abdomen is strongly linked to insulin resistance, cardiovascular risk, and inflammation. Tirzepatide users were also significantly more likely to hit the 20% and 25% weight loss thresholds that tend to produce the most dramatic metabolic improvements.

In patients with type 2 diabetes, the picture is similarly clear. The SURPASS-2 trial published in the New England Journal of Medicine compared all three doses of tirzepatide against semaglutide 1 mg in nearly 1,900 patients. Tirzepatide at every dose tested — 5 mg, 10 mg, and 15 mg — was both non-inferior and superior to semaglutide for HbA1c reduction. The 15 mg dose produced an average HbA1c drop of 2.30 percentage points versus 1.86 for semaglutide. Body weight losses were also significantly greater at every tirzepatide dose. A 2024 systematic review and network meta-analysis in Diabetologia, which pooled data from 28 randomized controlled trials and over 23,000 participants, confirmed that tirzepatide 15 mg was the most efficacious treatment for reducing HbA1c and body weight among all subcutaneous options evaluated.

So on the fat loss and glycemic control scoreboard, tirzepatide holds the edge. But the story becomes more nuanced when you look at heart health outcomes specifically.

Heart Failure, Mortality, and the Cardiovascular Picture

One of the most compelling emerging uses for both medications is in patients with heart failure with preserved ejection fraction (HFpEF) — a condition heavily driven by obesity and metabolic dysfunction, and one that has historically been very difficult to treat. A major 2025 analysis published in JAMA used US health care claims data from over 97,000 patients to evaluate real-world outcomes. Both semaglutide and tirzepatide reduced the composite risk of heart failure hospitalization or all-cause mortality by more than 40% compared to a placebo proxy — a staggering finding for a condition with few effective pharmacologic options.

Here’s where it gets interesting: despite tirzepatide’s clear advantage in weight loss, the head-to-head cardiovascular comparison in this study showed no meaningful difference between the two drugs for heart failure outcomes (HR 0.86, 95% CI 0.70–1.06 for tirzepatide versus semaglutide). This suggests that for certain outcomes — particularly cardiac ones — the mechanisms at play extend beyond simple weight reduction, and semaglutide may hold its own through pathways not fully captured by the scale. Both drugs carry significant cardiovascular benefit, and for men dealing with HFpEF alongside obesity or diabetes, either represents a meaningful clinical option.

The side effect profiles of the two drugs are broadly similar. Gastrointestinal symptoms — nausea, diarrhea, vomiting — are the most common adverse events with both medications, and they tend to be mild to moderate in severity, occurring primarily during dose escalation. In SURMOUNT-5, both groups experienced comparable GI event rates. Serious adverse events were slightly higher with tirzepatide in the SURPASS-2 diabetes trial (5–7% vs. 3%), though neither drug raised significant safety red flags across the broader evidence base.

The Unexpected Benefit: Appetite, Cravings, and Alcohol

Beyond the metabolic metrics, both semaglutide and tirzepatide are showing effects that researchers are only beginning to understand — particularly around reward-driven behavior. A 2023 study in Scientific Reports found that individuals with obesity taking either semaglutide or tirzepatide reported significantly lower alcohol intake, fewer drinks per drinking episode, reduced binge drinking odds, and lower AUDIT scores compared to both their pre-medication baseline and a control group. An analysis of over 68,000 social media posts found that 71% of alcohol-related content from GLP-1 users described craving reduction or decreased desire to drink.

This isn’t entirely surprising. GLP-1 receptors are present in brain regions associated with reward and impulse control. What it suggests is that these medications may quiet the broader noise of compulsive overconsumption — not just with food, but with alcohol and potentially other substances. For men navigating fat loss who also struggle with weekend drinking or reward-driven eating patterns, this is a meaningful secondary benefit worth factoring in.

What this research does not tell you is that medication replaces the fundamentals. Training, protein intake, sleep, and stress management remain the foundation of any serious physique or health goal. GLP-1 medications are a potent tool for reducing appetite and improving metabolic signaling, but the men seeing the best long-term results are combining pharmacology with progressive resistance training — which helps preserve lean mass during rapid weight loss — and dialing in nutrition to ensure adequate protein during a caloric deficit.

What This Means For You

If you’re weighing semaglutide against tirzepatide, the evidence now gives you a clearer answer than it did even a year ago. For pure weight loss, tirzepatide wins — and it’s not particularly close. For cardiovascular outcomes in the context of heart failure, both drugs perform impressively well, with no statistically meaningful difference between them. For blood sugar control in type 2 diabetes, tirzepatide again holds the edge at higher doses. The side effect burden is comparable. The dual-mechanism approach of tirzepatide appears to translate into superior metabolic outcomes for most people, which is why it’s increasingly becoming the first-choice recommendation in obesity medicine.

That said, semaglutide is not a consolation prize. It remains a highly effective, well-studied medication with years of real-world data behind it and proven cardiovascular benefits. Availability, cost, insurance coverage, and individual tolerability all factor into the equation. The best medication is the one you can consistently access, tolerate, and combine with the lifestyle habits that produce lasting results. Talk to your physician about what fits your situation — because the science is now clear enough that the conversation is worth having.